Evidence map›Paper›PMID 30050291›Full record

ArticlePatient preference and adherence2018

Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks.

Barry Hendin, Robert T Naismith, Sibyl E Wray, Deren Huang, Qunming Dong, Terrie Livingston, Daniel L Jones, Crystal Watson, Mehul Jhaveri

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Patient preference and adherence, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Barry HendinPhoenix Neurological Associates, Phoenix, AZ, USA.
Robert T NaismithDepartment of Neurology, Washington University School of Medicine, St Louis, MO, USA.
Sibyl E WrayHope Neurology MS Center, Knoxville, TN, USA.
Deren HuangMount Carmel Neuroscience and MDH Research, Westerville, OH, USA.
Qunming DongBiostatistics, Biogen, Cambridge, MA, USA.
Terrie LivingstonUS Medical, Biogen, Cambridge, MA, USA, mehul.jhaveri@biogen.com.
Daniel L JonesUS Medical, Biogen, Cambridge, MA, USA, mehul.jhaveri@biogen.com.
Crystal WatsonGlobal Value and Access, Biogen, Cambridge, MA, USA.
Mehul JhaveriUS Medical, Biogen, Cambridge, MA, USA, mehul.jhaveri@biogen.com.
Biogen (United States) · USMount Carmel Health · USPhoenix Neurological Associates · USWashington University in St. Louis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesPosthoc analysis of treatment satisfaction in patients switching to subcutaneous (SC) peginterferon beta-1a in the ALLOW study. PATIENTS AND

methodsPatients with relapsing multiple sclerosis treated with intramuscular interferon (IFN) beta-1a or SC IFN beta-1a or beta-1b remained on their current therapy for a 4-week run-in period, followed by a switch to SC peginterferon beta-1a 125 mcg every 2 weeks for 48 weeks. Treatment satisfaction was measured using the Treatment Satisfaction Questionnaire for Medication (TSQM), which covers effectiveness, side effects, convenience, and global satisfaction. Patients completed the TSQM at baseline (prior to starting the 4-week run-in period) and 4, 12, 24, 36, and 48 weeks after switching, and scores were analyzed for the overall population and compared to baseline. Patients reported the severity of flu-like symptoms (FLS) at baseline and with each peginterferon beta-1a injection; clinicians evaluated the occurrence of injection-site reactions (ISRs) after the first dose of peginterferon beta-1a and every 12 weeks thereafter. TSQM scores were stratified by the presence of FLS or ISRs during the study period and by prior IFN therapy use.

resultsFor the overall population (n=194), convenience and global satisfaction scores significantly improved from baseline at all time points, and side effect satisfaction scores significantly improved up to week 36. Convenience scores significantly improved regardless of FLS, ISRs, or prior IFN therapy. Patients without FLS during the study period showed significant improvements in global satisfaction, but not side effect satisfaction, versus those with FLS. Patients switching from SC IFN therapies achieved greater improvements in treatment satisfaction than patients who switched from intramuscular IFN beta-1a.

conclusionsSwitching relapsing multiple sclerosis patients to SC peginterferon beta-1a from other IFN therapies significantly improved treatment satisfaction and convenience.

Indexed as

interferon beta-1ainterferon beta-1bpatient-reported outcomespeginterferon beta-1aquality of liferelapsing multiple sclerosistreatment satisfactionTreatment Satisfaction Questionnaire for MedicationTSQM

Identifiers

PMID30050291
PMCPMC6056153
OpenAlexW2884937300

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.